These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 9753052)

  • 1. Absence of Bruton's tyrosine kinase (Btk) mutations in patients with acute myeloid leukaemia.
    Ritis K; Speletas M; Tsironidou V; Pardali E; Kanariou M; Moschese V; Orlandi P; Skordala M; Rossi P; Kartalis G; Bourikas G; Sideras P
    Br J Haematol; 1998 Sep; 102(5):1241-8. PubMed ID: 9753052
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Analysis of Btk mutations in patients with X-linked agammaglobulinaemia (XLA) and determination of carrier status in normal female relatives: a nationwide study of Btk deficiency in Greece.
    Speletas M; Kanariou M; Kanakoudi-Tsakalidou F; Papadopoulou-Alataki E; Arvanitidis K; Pardali E; Constantopoulos A; Kartalis G; Vihinen M; Sideras P; Ritis K
    Scand J Immunol; 2001 Sep; 54(3):321-7. PubMed ID: 11555397
    [TBL] [Abstract][Full Text] [Related]  

  • 3. X-chromosome inactivation and mutation pattern in the Bruton's tyrosine kinase gene in patients with X-linked agammaglobulinemia. Italian XLA Collaborative Group.
    Moschese V; Orlandi P; Plebani A; Arvanitidis K; Fiorini M; Speletas M; Mella P; Ritis K; Sideras P; Finocchi A; Livadiotti S; Rossi P
    Mol Med; 2000 Feb; 6(2):104-13. PubMed ID: 10859027
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification of nine novel mutations in the Bruton's tyrosine kinase gene in X-linked agammaglobulinaemia patients.
    Orlandi P; Ritis K; Moschese V; Angelini F; Arvanitidis K; Speletas M; Sideras P; Plebani A; Rossi P
    Hum Mutat; 2000 Jan; 15(1):117. PubMed ID: 10612838
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bruton's tyrosine kinase: potential target in human multiple myeloma.
    Liu Y; Dong Y; Jiang QL; Zhang B; Hu AM
    Leuk Lymphoma; 2014 Jan; 55(1):177-81. PubMed ID: 23581641
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Activity of Bruton's tyrosine-kinase inhibitor ibrutinib in patients with CD117-positive acute myeloid leukaemia: a mechanistic study using patient-derived blast cells.
    Rushworth SA; Pillinger G; Abdul-Aziz A; Piddock R; Shafat MS; Murray MY; Zaitseva L; Lawes MJ; MacEwan DJ; Bowles KM
    Lancet Haematol; 2015 May; 2(5):e204-11. PubMed ID: 26688095
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bruton's tyrosine kinase is not essential for LPS-induced activation of human monocytes.
    Pérez de Diego R; López-Granados E; Pozo M; Rodríguez C; Sabina P; Ferreira A; Fontan G; García-Rodríguez MC; Alemany S
    J Allergy Clin Immunol; 2006 Jun; 117(6):1462-9. PubMed ID: 16751014
    [TBL] [Abstract][Full Text] [Related]  

  • 8. DNA-based mutation analysis of Bruton's tyrosine kinase gene in patients with X-linked agammaglobulinaemia.
    Vorechovský I; Vihinen M; de Saint Basile G; Honsová S; Hammarström L; Müller S; Nilsson L; Fischer A; Smith CI
    Hum Mol Genet; 1995 Jan; 4(1):51-8. PubMed ID: 7711734
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification of novel Bruton's tyrosine kinase mutations in 10 unrelated subjects with X linked agammaglobulinaemia.
    Brooimans RA; van den Berg AJ; Rijkers GT; Sanders LA; van Amstel JK; Tilanus MG; Grubben MJ; Zegers BJ
    J Med Genet; 1997 Jun; 34(6):484-8. PubMed ID: 9192269
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Molecular and structural characterization of five novel mutations in the Bruton's tyrosine kinase gene from patients with X-linked agammaglobulinemia.
    Saha BK; Curtis SK; Vogler LB; Vihinen M
    Mol Med; 1997 Jul; 3(7):477-85. PubMed ID: 9260159
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Bruton's tyrosine kinase gene is expressed throughout B cell differentiation, from early precursor B cell stages preceding immunoglobulin gene rearrangement up to mature B cell stages.
    de Weers M; Verschuren MC; Kraakman ME; Mensink RG; Schuurman RK; van Dongen JJ; Hendriks RW
    Eur J Immunol; 1993 Dec; 23(12):3109-14. PubMed ID: 8258324
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Deletion within the Src homology domain 3 of Bruton's tyrosine kinase resulting in X-linked agammaglobulinemia (XLA).
    Zhu Q; Zhang M; Rawlings DJ; Vihinen M; Hagemann T; Saffran DC; Kwan SP; Nilsson L; Smith CI; Witte ON; Chen SH; Ochs HD
    J Exp Med; 1994 Aug; 180(2):461-70. PubMed ID: 7519238
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mutation screening of the BTK gene in 56 families with X-linked agammaglobulinemia (XLA): 47 unique mutations without correlation to clinical course.
    Holinski-Feder E; Weiss M; Brandau O; Jedele KB; Nore B; Bäckesjö CM; Vihinen M; Hubbard SR; Belohradsky BH; Smith CI; Meindl A
    Pediatrics; 1998 Feb; 101(2):276-84. PubMed ID: 9445504
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Defective expression of Bruton's tyrosine kinase in acute lymphoblastic leukemia.
    Goodman PA; Wood CM; Vassilev AO; Mao C; Uckun FM
    Leuk Lymphoma; 2003 Jun; 44(6):1011-8. PubMed ID: 12854903
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bruton's tyrosine kinase expression and activity in X-linked agammaglobulinaemia (XLA): the use of protein analysis as a diagnostic indicator of XLA.
    Gaspar HB; Lester T; Levinsky RJ; Kinnon C
    Clin Exp Immunol; 1998 Feb; 111(2):334-8. PubMed ID: 9486400
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Kinase mutant Btk results in atypical X-linked agammaglobulinaemia phenotype.
    Gaspar HB; Ferrando M; Caragol I; Hernandez M; Bertran JM; De Gracia X; Lester T; Kinnon C; Ashton E; Espanol T
    Clin Exp Immunol; 2000 May; 120(2):346-50. PubMed ID: 10792386
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Role of Bruton's tyrosine kinase in B cells and malignancies.
    Pal Singh S; Dammeijer F; Hendriks RW
    Mol Cancer; 2018 Feb; 17(1):57. PubMed ID: 29455639
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Screening of genomic DNA to identify mutations in the gene for Bruton's tyrosine kinase.
    Conley ME; Fitch-Hilgenberg ME; Cleveland JL; Parolini O; Rohrer J
    Hum Mol Genet; 1994 Oct; 3(10):1751-6. PubMed ID: 7849697
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Expression of Bruton's tyrosine kinase in B lymphoblastoid cell lines from X-linked agammaglobulinaemia patients.
    De Weers M; Dingjan GM; Brouns GS; Kraakman ME; Mensink RG; Lovering RC; Schuurman RK; Borst J; Hendriks RW
    Clin Exp Immunol; 1997 Feb; 107(2):235-40. PubMed ID: 9030858
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bruton's tyrosine kinase is present in normal platelets and its absence identifies patients with X-linked agammaglobulinaemia and carrier females.
    Futatani T; Watanabe C; Baba Y; Tsukada S; Ochs HD
    Br J Haematol; 2001 Jul; 114(1):141-9. PubMed ID: 11472359
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.